To study the clinical efficacy and safety of direct-acting oral anticoagulants in patients with atrial fibrillation treated in a real clinical setting.In this study, 356 AF patients aged 50 to 75 years with a creatinine clearance rate of at least 50 ml/min were observed. Patients were divided into 3 groups according to the type of POAC taken: Group 1 (n=120) took rivaroxaban at a dose of 20 mg/1 g/day; Group 2 (n=112) took dabigatran etexilate at a dose of 150 g/day mg/1 g/day 2 times a day; and Group 3 (n=124) took apixaban at a dose of 5 mg/2 times a day. The groups of patients were compared by age, concomitant pathology, risk of thromboembolic and hemorrhagic complications. The study period was 2 years from the time of drug administration. The endpoints were thromboembolic complications, major bleeding events and death from any cause.